Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
424B7
Regulatory Filings Classification · 82% confidence The document is a prospectus supplement filed under SEC Rule 424(b)(7) updating a previously filed prospectus for the resale of existing shares and warrants by selling stockholders. It is not an annual or quarterly report (10-K, IR), earnings release, management discussion, or other financial statement. It is an SEC offering document without a dedicated category for “prospectus supplement,” so it falls under the fallback category for general regulatory filings (RNS).
2026-05-15 English
10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
Regulatory Filings Classification · 90% confidence The document is a SEC Form 8-K “Current Report” filing under the Exchange Act. It reports the issuance of a press release on quarterly results and an updated corporate presentation (attached as exhibits), but contains no substantive financial statements itself. It is therefore a regulatory filing (fallback category) rather than an earnings release, annual/interim report, or investor presentation by itself. Thus it should be classified as Regulatory Filings (RNS).
2026-05-13 English
ARS - Aprea Therapeutics, Inc. (0001781983) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
424B3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares of common stock underlying pre-funded warrants and common stock purchase warrants. It includes detailed information about the offering, use of proceeds, risk factors, company overview, and other disclosures typical of a prospectus. The document is not an annual report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report. It is a capital markets document related to financing activities, specifically a resale registration statement prospectus. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus, not just an announcement or certification.
2026-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.